These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 23661145

  • 1. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Pouton CW, Porter CJ, LFCS Consortium.
    Pharm Res; 2013 Dec; 30(12):3059-76. PubMed ID: 23661145
    [Abstract] [Full Text] [Related]

  • 2. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Pouton CW, Porter CJ.
    Mol Pharm; 2012 Nov 05; 9(11):3286-300. PubMed ID: 23030411
    [Abstract] [Full Text] [Related]

  • 3. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Porter CJ, Pouton CW, Communicated on Behalf of the LFCS Consortium.
    J Pharm Sci; 2014 Aug 05; 103(8):2441-55. PubMed ID: 24985238
    [Abstract] [Full Text] [Related]

  • 4. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R, Williams HD, Warren DB, Mohsin K, Porter CJ, Pouton CW.
    Eur J Pharm Sci; 2013 Jul 16; 49(4):748-60. PubMed ID: 23684915
    [Abstract] [Full Text] [Related]

  • 5. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA, Chalmers DK, Pouton CW, Porter CJH.
    Mol Pharm; 2018 Jun 04; 15(6):2355-2371. PubMed ID: 29659287
    [Abstract] [Full Text] [Related]

  • 6. Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.
    Devraj R, Williams HD, Warren DB, Porter CJ, Pouton CW.
    J Pharm Sci; 2014 Apr 04; 103(4):1050-63. PubMed ID: 24470073
    [Abstract] [Full Text] [Related]

  • 7. A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.
    Crum MF, Trevaskis NL, Williams HD, Pouton CW, Porter CJ.
    Pharm Res; 2016 Apr 04; 33(4):970-82. PubMed ID: 26703975
    [Abstract] [Full Text] [Related]

  • 8. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL, Trevaskis NL, Feeney OM, Edwards GA, Perlman ME, Ambler CM, Porter CJH.
    Mol Pharm; 2017 Dec 04; 14(12):4525-4538. PubMed ID: 29076741
    [Abstract] [Full Text] [Related]

  • 9. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.
    Crum MF, Trevaskis NL, Pouton CW, Porter CJ.
    Mol Pharm; 2017 Feb 06; 14(2):394-405. PubMed ID: 28002666
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y, Doi H, Katano T, Kasaoka S.
    Eur J Pharm Sci; 2021 Feb 01; 157():105604. PubMed ID: 33098990
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.
    Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ.
    Pharm Res; 2013 Dec 01; 30(12):2976-92. PubMed ID: 23824582
    [Abstract] [Full Text] [Related]

  • 15. Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.
    Stillhart C, Imanidis G, Griffin BT, Kuentz M.
    Pharm Res; 2014 Dec 01; 31(12):3426-44. PubMed ID: 24962509
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.